title: Phase I and pharmacologic study of docetaxel and cisplatin in patients with advanced solid tumors.
abstract: OBJECTIVE
  This phase I study was performed to assess the feasibility of the combination of docetaxel and cisplatin and to determine the maximum-tolerated dose (MTD) and the side effects with an emphasis on sequence-dependent side effects.
  
  
  METHODS
  Patients who were not pretreated with taxanes or cisplatin derivatives and who had received no more than one prior combination chemotherapy regimen or two single-agent regimens were entered. Treatment consisted of docetaxel given as a 1-hour infusion followed by cisplatin as a 3-hour infusion (schedule A), or cisplatin followed by docetaxel (schedule B). Docetaxel doses ranged from 55 to 100 mg/m2 and cisplatin doses from 50 to 100 mg/m2.
  
  
  RESULTS
  Leukocytopenia and granulocytopenia were common (overall, 90%; grade 3 or 4, 87%), short-lasting, and docetaxel dose-dependent. Infections and neutropenic fever occurred in 10% and 4.5% of courses, respectively. Nonhematologic toxicities were mild to moderate and included alopecia, nausea, vomiting, diarrhea, mucositis, neurotoxicity, fluid retention, and skin and nail toxicity. There were no significant differences in pharmacokinetic parameters between schedules A and B. Tumor responses included one complete response (CR) and nine partial responses (PRs).
  
  
  CONCLUSIONS
  The dose levels docetaxel 100 mg/m2 plus cisplatin 75 mg/m2 and docetaxel 85 mg/m2 plus cisplatin 100 mg/m2 appeared to be manageable. At these dose levels, the median relative dose-intensity was high and 81% and 88% of all cycles, respectively, could be given at full dose. Schedule A is advocated for further treatment.
authors.affiliation: Department of Medical Oncology and Neuro-Oncology, Rotterdam Cancer Institute (Daniel den Hoed Kliniek) and University Hospital, the Netherlands.
authors.forename: L C
authors.initials: LC
authors.lastname: Pronk
authors.forename: J H
authors.initials: JH
authors.lastname: Schellens
authors.forename: A S
authors.initials: AS
authors.lastname: Planting
authors.forename: M J
authors.initials: MJ
authors.lastname: van den Bent
authors.forename: P H
authors.initials: PH
authors.lastname: Hilkens
authors.forename: M E
authors.initials: ME
authors.lastname: van der Burg
authors.forename: M
authors.initials: M
authors.lastname: de Boer-Dennert
authors.forename: J
authors.initials: J
authors.lastname: Ma
authors.forename: C
authors.initials: C
authors.lastname: Blanc
authors.forename: M
authors.initials: M
authors.lastname: Harteveld
authors.forename: R
authors.initials: R
authors.lastname: Bruno
authors.forename: G
authors.initials: G
authors.lastname: Stoter
authors.forename: J
authors.initials: J
authors.lastname: Verweij
mesh_terms: D000328:Adult; D000368:Aged; D000380:Agranulocytosis / Q000139:chemically induced; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002945:Cisplatin / Q000008:administration & dosage / Q000009:adverse effects; D000077143:Docetaxel; D005240:Feasibility Studies; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007970:Leukopenia / Q000139:chemically induced; D008297:Male; D008875:Middle Aged; D009325:Nausea / Q000139:chemically induced; D009369:Neoplasms / Q000188:drug therapy*; D017239:Paclitaxel / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives; D043823:Taxoids; D014839:Vomiting / Q000139:chemically induced
chemical_list: D043823:Taxoids; D000077143:Docetaxel; D017239:Paclitaxel; D002945:Cisplatin